Application of aldose reductase as intervention target spot in reversing drug resistance of liver cancer system treatment drug or treating liver cancer
By interfering with the expression level of aldose reductase, regulating the metabolic pathway of liver cancer cells, combining inhibitors and targeted drugs, the problem of resistance to drug-free active aldehyde-based drugs in patients with liver cancer is solved, and the treatment effect and patient quality of life are improved.
Patent Information
- Application Number
- CN202411142643.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-26
AI Technical Summary
Patients with liver cancer develop resistance to systemic therapeutic drugs that do not contain active aldehyde groups, resulting in a significant reduction in the treatment effect and affecting survival and quality of life.
By interfering with the expression level of aldose reductase (AKR1B1), the glycolipid metabolism pathway and glutathione metabolism pathway in liver cancer cells were regulated, and inhibitors such as epalstat combined with drugs such as lenvatinib were used to reverse drug resistance.
It significantly improves the sensitivity of liver cancer cells to systemic therapeutic drugs, extends survival, improves quality of life, and provides more effective liver cancer treatment options.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biology, medical treatment and medical device technology, and specifically relates to the use of aldose reductase as an intervention target in reversing the drug resistance of systemic therapeutic drugs for liver cancer or in treating liver cancer, and especially relates to the use of aldose reductase as an intervention target in the preparation of drugs for reversing the drug resistance of systemic therapeutic drugs for liver cancer (especially anti-liver cancer drugs that do not contain active aldehyde groups (such as lenvatinib and / or sorafenib)) and / or in the preparation of drugs for treating liver cancer. Background Art
[0002] Liver cancer poses a great threat to the health of Chinese people. Its harmfulness is mainly reflected in its high invasiveness and the lack of obvious symptoms in the early stages, which means that many patients have already entered the late stage when diagnosed, greatly increasing the difficulty of treatment. As a malignant tumor, liver cancer can spread rapidly to other parts of the body through the blood and lymphatic systems, forming distant metastases. Advanced liver cancer is mainly treated with systemic treatment methods, mainly to relieve symptoms, delay disease progression, and improve the quality of life of patients.
[0003] Drug resistance is a serious problem in the systemic treatment of liver cancer. The consequence of liver cancer resistance is a significant decrease in the effectiveness of treatment and increasingly severe clinical challenges. When patients receive systemic treatment, especially chemotherapy and targeted therapy, they may develop drug resistance, resulting in the failure of the originally effective treatment plan. This not only makes tumor cells more difficult to control, thereby promoting the malignant growth of tumors, but also limits the flexibility of doctors in treatment options. In addition, liver cancer resistance also increases the pain and burden of patients, prolongs the progression of the disease, and greatly affects the survival and quality of life of patients. To overcome this dilemma, it is urgent to strengthen scientific research, deeply understand the mechanism of drug resistance, and develop new treatment strategies to improve the treatment effect and survival rate of liver cancer patients.
[0004] Aldose reductase (AKR1B1, also referred to as AR in this article) is a NADPH-dependent oxidoreductase that catalyzes the reduction of various aldehydes and carbonyl compounds (including monosaccharides). It has been found that its high expression in human hepatoma cells (HepG2) may make human hepatoma cells resistant to certain anti-hepatocellular carcinoma drugs containing active aldehyde groups (such as daunorubicin, mitomycin and epirubicin) (Lee KWY, Ko BCB, Jiang Z, et al. Overexpression of aldose reductase in liver cancers may contribute to drug resistance [J]. Anti-cancer Drugs, 2001, 12(2): 129-132.). This is because after HepG2 cells highly express AR, exogenous drugs containing active aldehyde groups are effectively reduced by AR in the cells, reducing drug cytotoxicity and induced cell apoptosis, resulting in cell resistance to certain anti-liver cancer drugs containing active aldehyde groups. This resistance can be reversed by adding AR inhibitors (ARIs) because ARIs can prevent AR from detoxifying these anti-liver cancer drugs containing active aldehyde groups.
[0005] However, currently, among the common clinical targeted drugs / chemotherapeutic drugs for systemic treatment of liver cancer, anti-liver cancer drugs that do not contain active aldehyde groups (such as lenvatinib, sorafenib, regorafenib, gefitinib, lapatinib, irinotecan, fluorouracil, oxaliplatin, etc.) are mainly used. When liver cancer patients develop resistance to these drugs, the efficacy of these drugs will be significantly reduced, which not only makes tumor cells more difficult to control, but also greatly affects the survival and quality of life of patients. Therefore, there is an urgent need for a method to reverse the resistance of liver cancer patients to these anti-liver cancer drugs that do not contain active aldehyde groups and provide more effective liver cancer treatment options. Summary of the invention
[0006] In response to one or more of the problems existing in the prior art, the first aspect of the present invention provides the use of aldose reductase as a target in regulating the activity of the glycolipid metabolic pathway and the glutathione metabolic pathway of liver cancer cells. Specifically, when the expression of aldose reductase is increased (or overexpressed), the activity of the glycolipid metabolic pathway and the glutathione metabolic pathway of liver cancer cells can be increased, and when the expression of aldose reductase is reduced (or its expression is knocked down), the activity of the glycolipid metabolic pathway and the glutathione metabolic pathway of liver cancer cells can be reduced.
[0007] The second aspect of the present invention provides the use of an agent for interfering with aldose reductase expression in the preparation of a drug for reversing the resistance of liver cancer patients to systemic liver cancer therapeutic drugs, wherein the systemic liver cancer therapeutic drug is an anti-liver cancer drug that does not contain an active aldehyde group.
[0008] In some embodiments, the drug reverses the resistance of liver cancer patients to systemic treatment drugs for liver cancer by reducing the activity of the glycolipid metabolism pathway and the glutathione metabolism pathway in liver cancer tissues or cells of liver cancer patients.
[0009] The third aspect of the present invention provides the use of an agent for interfering with aldose reductase expression in the preparation of a drug for treating liver cancer patients resistant to systemic liver cancer treatment drugs, wherein the systemic liver cancer treatment drug is an anti-liver cancer drug that does not contain an active aldehyde group.
[0010] The fourth aspect of the present invention provides the use of an agent for intervening in aldose reductase expression in combination with an anti-liver cancer targeted drug in the preparation of a drug for treating liver cancer patients resistant to systemic liver cancer treatment drugs, wherein the systemic liver cancer treatment drug is an anti-liver cancer drug that does not contain an active aldehyde group.
[0011] In some embodiments, the agent that interferes with the expression of aldose reductase is Epalrestat, and the anti-liver cancer targeted drug is Lenvatinib.
[0012] In some embodiments, the anti-liver cancer drugs that do not contain active aldehyde groups include lenvatinib, sorafenib, regorafenib, gefitinib, lapatinib, irinotecan, fluorouracil, and oxaliplatin.
[0013] In some embodiments, the agent that interferes with the expression of aldose reductase is an inhibitor of aldose reductase.
[0014] In some embodiments, the inhibitors of aldose reductase include Epalrestat, Sulindac, Fidarestat, and Ranirestat.
[0015] In some embodiments, the agent intervening in the expression of aldose reductase is an agent that knocks down the expression level of the AKR1B1 gene.
[0016] In some embodiments, the agent for knocking down the expression level of the AKR1B1 gene is an agent for knocking down the expression level of the AKR1B1 gene based on the principle of lentiviral transfection.
[0017] A fifth aspect of the present invention provides a drug for treating liver cancer patients who are resistant to systemic liver cancer treatment drugs, wherein the systemic liver cancer treatment drug is an anti-liver cancer drug that does not contain an active aldehyde group, and the drug comprises a combination of epalrestat and lenvatinib.
[0018] The inventors have found that the expression level of AKR1B1 in liver cancer tissues or cells is closely related to the resistance level to systemic therapeutic drugs that do not contain active aldehyde groups (such as lenvatinib and sorafenib, etc.), and the resistance of drug-resistant cells to these systemic therapeutic drugs that do not contain active aldehyde groups can be reversed by intervening (such as interfering or knocking down) the expression level of AKR1B1, thereby reversing the drug-resistant cells into cells that are sensitive to these systemic therapeutic drugs that do not contain active aldehyde groups. Therefore, the reagent that intervenes in AKR1B1 can be used to reverse the resistance of liver cancer patients to anti-liver cancer drugs that do not contain active aldehyde groups, and can be used alone or in combination with anti-liver cancer targeted drugs to treat liver cancer patients who are resistant to anti-liver cancer drugs that do not contain active aldehyde groups, and the results of the examples show that when the inhibitor of AKR1B1, epalrestat, is used in combination with the anti-liver cancer targeted drug lenvatinib to treat drug-resistant cells or resistant tumor-bearing animal models, a synergistic effect can be exerted. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 A schematic diagram of the construction process of the lenvatinib and sorafenib liver cancer resistant cell model (A) and the morphology of the constructed hepatocellular carcinoma resistant cell model under bright field microscopy (B) are shown.
[0020] Figure 2 The single-cell sequencing results of Huh7 LR resistant cells and Huh-7 P original cells are shown, where panels A and B represent the dimensionality reduction clustering diagram (A), cell component analysis diagram (B), pseudo-time series analysis diagram (C), and key gene expression difference diagram (D) of Huh-7 P and Huh-7 LR, respectively.
[0021] Figure 3 The sensitivity curves and calculated IC values of the original cell line and the drug-resistant cell line to lenvatinib (A) and sorafenib (B) evaluated by CCK-8 assay are shown. 50 value.
[0022] Figure 4 A heat map showing the cell viability of the constructed hepatocellular carcinoma resistant cell model after treatment with 6 drugs.
[0023] Figure 5 The live / dead probe staining status after application of targeting / chemotherapeutic drugs to 3D microtissues (A) and the statistical results of fluorescently stained dead cells (B) are shown.
[0024] Figure 6 Shown are the statistical results of cell mortality after treatment of 3D cell spheroids with lenvatinib or sorafenib.
[0025] Figure 7 The results of cell activity detection after combined drug administration to the original strain cells and the drug-resistant strain cells are shown.
[0026] Figure 8 The results of immunofluorescence detection of the original strain cells and the drug-resistant strain cells (A), the results of protein immunoblotting quantitative detection (B), and the results of immunofluorescence and immunohistochemistry staining of tissues from liver cancer patients (C) are shown.
[0027] Fig. 9 The relationship between the establishment of resistance to lenvatinib and sorafenib and the expression level of AKR1B1 is shown (A and B), as well as the correlation analysis results between the resistance of resistant cells and the expression level of AKR1B1 (C).
[0028] Fig.10 The results of triglyceride content detection of the original strain cells and the drug-resistant strain cells are shown.
[0029] Fig.11 The NAD of the original strain cells and the drug-resistant strain cells is shown + and NADH content (A) and NADPH and NADP + (B) Test results of content.
[0030] Fig.12 The results of glycolysis level / capacity / reserve detection (A) and ATP source ratio analysis (B) of the original cell line and the drug-resistant cell line are shown.
[0031] Fig.13 The high-content real-time imaging system for tracking cellular fatty acid uptake in the original strain cells and the drug-resistant strain cells (A) and the fatty acid uptake density at 8 representative time points (B) are shown.
[0032] Fig.14 The results of the detection of fatty acid β-oxidation levels in the original strain cells and the drug-resistant strain cells are shown.
[0033] Fig.15 The results of combined transcriptomics and metabolomics to identify key targets are shown.
[0034] Fig.16 The results of AKR1B1 protein level detection in drug-resistant cell AKR1B1 knockdown cell line (A) and AKR1B1 gene transfection efficiency displayed by GFP fluorescence (B) are shown.
[0035] Fig.17 The figure shows the changes in lipid metabolism phenotype after knockdown of AKR1B1 in drug-resistant cells, where amplitudes A and B represent the results of cellular triglyceride level detection, intracellular lipid droplet level detection, and intracellular fatty acid β-oxidation rate detection, respectively.
[0036] Fig.18Shown are the nude mouse tumor tissue and mouse entity image (A), the nude mouse tumor volume growth curve (B) and the nude mouse tumor weight statistics (C).
[0037] Fig.19 Shown are the results of Western blot experiments on the expression of aldose reductase in tumor-bearing tissues from two animal models.
[0038] Fig. 20 The AKR1B1 levels in the serum of liver cancer patients who did not use systemic therapeutic drugs and patients who used drugs for a long time are shown.
[0039] Fig.21 Shown are the sensitivity test results of Huh-7 LR:sh-AKR1B1-1 to lenvatinib (A), the sensitivity test results of Huh-7 SR:sh-AKR1B1-1 to sorafenib (B), and the heat maps of the sensitivity of Huh-7 LR:sh-AKR1B1-1 and Huh-7 SR:sh-AKR1B1-1 to various systemic therapeutic drugs (C and D).
[0040] Fig. 22 The figures show the tumor tissue and mouse solid image (A) of nude mice with AKR1B1 knockdown, the statistical results of the tumor weight of nude mice (B), and the tumor volume growth curve of nude mice (C).
[0041] Fig.23 The results of Western blotting experiments to detect the levels of key genes in the glutathione metabolic pathway in nude mouse tumor tissues are shown.
[0042] Fig.24 The cell survival curves (A) and IC values of two resistant cell lines (Huh-7 LR and Huh-7 SR) and the original cell line after treatment with epalrestat are shown. 50 (B), and the results of the combined use of epalrestat with lenvatinib or sorafenib (C and D).
[0043] Fig.25 Shown are the tumor tissue and mouse solid image (A) of nude mice after treatment with epalrestat, lenvatinib, or the combination of the two, the tumor volume growth curve of nude mice (B), and the statistical results of the tumor weight of nude mice (C). DETAILED DESCRIPTION
[0044] In view of the lack of methods for reversing the drug resistance of liver cancer patients to some systemic therapeutic drugs that do not contain active aldehyde groups in the prior art, the present invention, based on the discovery that the expression level of AKR1B1 is closely related to its resistance level to systemic therapeutic drugs that do not contain active aldehyde groups, further discovered that by intervening (e.g., interfering or knocking down) the expression level of AKR1B1, the resistance of resistant cells to these systemic therapeutic drugs that do not contain active aldehyde groups can be reversed, and then the resistant cells can be reversed into cells that are sensitive to these systemic therapeutic drugs that do not contain active aldehyde groups. Thus, reagents that intervene in the expression of AKR1B1 can be used to reverse the resistance of liver cancer patients to some systemic therapeutic drugs that do not contain active aldehyde groups, as well as to assist in the treatment of resistant liver cancer. The present invention is achieved based on the following research results.
[0045] The inventors have demonstrated the importance of lipid metabolism reprogramming and glutathione metabolic pathways for drug-resistant cells to maintain their own growth and resist survival pressure by constructing Huh-7 original strain cell models and lenvatinib / sorafenib resistant strain cell models (described in detail in the following examples), and through in vitro and in vivo experiments. Specifically, metabolic reprogramming detection experiments such as NAD (H) and NADP (H) energy and anabolism levels, glycolysis levels, glycolysis energy supply, triglyceride levels, lipid droplet numbers, and fatty acid energy supply have demonstrated that the metabolic levels of hepatocellular carcinoma drug-resistant cells are significantly more active than those of original strain cells. Drug-resistant cells adapt to stressful environments by increasing energy supply and material metabolism levels, which is also the cause of drug resistance, which is significantly different from the reason for the increased drug resistance of HepG2 cells to certain anti-tumor drugs containing active aldehyde groups found by KWY Lee et al. The inventors further found through transcriptome and metabolomics sequencing data analysis that the related molecules and metabolites of the glycolipid metabolism pathway and the glutathione metabolism pathway were significantly upregulated, indicating that the drug resistance of tumor cells is related to the activity of the above two pathways, among which the glycolipid metabolism pathway affects the energy supply of cells and promotes the "birth" of tumor cells, while the glutathione metabolism pathway affects the oxidative stress of cells and inhibits the "death" of tumor cells. In addition, the inventors also found an important molecule that affects these two pathways, namely AKR1B1, in the pathway enrichment and protein interaction network. Subsequently, the inventors tested the expression level of AKR1B1 in the constructed Huh-7 original strain cell model and the lenvatinib / sorafenib resistant strain cell model. The results showed that the expression level of AKR1B1 in the resistant strain cells was significantly upregulated compared with the original strain cells, and the expression level of AKR1B1 in the cancer tissues of patients with hepatocellular carcinoma who had long-term systemic treatment was also significantly increased compared with patients who had not undergone systemic treatment, indicating that the expression level of AKR1B1 has a high predictive value for the drug resistance or sensitivity of liver cancer cells. In addition, the inventors also found that the content of AKR1B1 in the serum of patients with hepatocellular carcinoma who had long-term systemic treatment was significantly higher than that in the serum of patients who had not undergone systemic treatment. Therefore, the possibility of drug resistance in liver cancer patients can be effectively predicted by detecting the content of AKR1B1 in the serum of liver cancer patients. On this basis, the inventors further studied whether the drug sensitivity of drug-resistant cells would be changed by intervening in the expression of AKR1B1. The results showed that when the expression level of AKR1B1 in drug-resistant cells was reduced, its sensitivity to a variety of targeted drugs and chemotherapeutic drugs was significantly increased. This result proves that the resistance of drug-resistant cells to systemic therapeutic drugs that do not contain active aldehyde groups can be reversed by intervening in the expression level of AKR1B1, for example, by reducing the activity of the glycolipid metabolic pathway and the glutathione metabolic pathway of liver cancer tissues or cells of liver cancer patients to reverse the resistance of liver cancer patients to liver cancer systemic therapeutic drugs, and thus can be used for adjuvant treatment of drug-resistant liver cancer.
[0046] The content of the present invention is described in detail below with reference to specific embodiments and drawings.
[0047] In the following, only some exemplary embodiments are briefly described. As those skilled in the art will appreciate, the described embodiments may be modified in various ways without departing from the spirit or scope of the present invention. Therefore, the drawings and descriptions are considered to be exemplary and non-restrictive in nature.
[0048] The methods used in the following examples are all conventional methods unless otherwise specified. For specific steps, please refer to: Molecular Cloning: A Laboratory Manual (Sambrook, J., Russell, David W., Molecular Cloning: A Laboratory Manual, 3rd edition, 2001, NY, Cold Spring Harbor).
[0049] The methods for obtaining various biological materials described in the examples are only provided as a way of obtaining them in an experiment to achieve the specific disclosed purpose, and should not be construed as limiting the sources of the biological materials of the present invention. In fact, the sources of the biological materials used are extensive, and any biological materials that can be obtained without violating laws and moral ethics can be replaced and used according to the instructions in the examples.
[0050] Example 1: Construction of a hepatocellular carcinoma drug-resistant cell model and identification of its drug sensitivity
[0051] (1.1) Construction of drug-resistant hepatocellular carcinoma cell model
[0052] To establish a drug-resistant cell model of hepatocellular carcinoma, a long-term drug-incremental induction method was used in this experiment. The original Huh-7 cell line (purchased from the National Biomedical Experimental Cell Resource Bank, also referred to as Huh-7 P in this article) was cultured in a medium containing two first-line targeted anti-liver cancer drugs, Lenvatinib (Lenvatinib, MedChemExpress, HY-10981) and Sorafenib (Sorafenib, MedChemExpress, HY-10201A). Figure 1 Panel A in the middle shows a schematic diagram of the construction process of the lenvatinib and sorafenib liver cancer resistant cell model. Specifically, the following steps are included:
[0053] 1.1) Lenvatinib / sorafenib was added to the complete culture medium by ultrasound and vortexing. The initial concentration of the two drugs was 1 μM; the formula of the complete culture medium was: high-glucose DMEM basal medium (Gibco) + 10% fetal bovine serum + 1% double antibiotics (penicillin + streptomycin), 37°C, 5% CO 2 Cultivated under conditions;
[0054] 1.2) exposing Huh-7 original strain cells to an initial dose of 1 μM lenvatinib / sorafenib prepared in step 1.1) above, and refreshing the culture medium every 2 days;
[0055] 1.3) After that, the stable cell line is placed under a concentration of lenvatinib / sorafenib, and the concentration of lenvatinib / sorafenib is gradually increased at a rate of 1.0-2.0 μM per week, and finally maintained in a medium containing 20 μM lenvatinib / 5 μM sorafenib; culture and passage are maintained at this concentration. During this process, if the cell adapts to unstable growth, the drug concentration can be traced back to the stage, and the induction gradient can be slowly increased again after stabilization;
[0056] 1.4) After about 10 / 6 months, a hepatocellular carcinoma resistant cell model (also referred to as resistant cell in the present invention) resistant to lenvatinib / sorafenib can be successfully constructed, wherein the hepatocellular carcinoma resistant cell model resistant to lenvatinib is named Huh7 LR, and the hepatocellular carcinoma resistant cell model resistant to sorafenib is named Huh7 SR. Figure 1 Panel B shows the morphology of the constructed hepatocellular carcinoma drug-resistant cell model under bright field microscopy.
[0057] (1.2) Differences between drug-resistant hepatocellular carcinoma cells and original hepatocellular carcinoma cells
[0058] This experiment performed single-cell sequencing on Huh7 LR resistant cells and Huh-7 P original cells (a technology that performs high-throughput sequencing analysis of the genome, transcriptome, and epigenome at the single cell level. It can reveal the gene structure and gene expression status of a single cell and reflect the heterogeneity between cells). The results are as follows Figure 2As shown in the figure, A represents the dimensionality reduction clustering diagram of Huh-7P and Huh-7 LR, and it can be seen that the two cells are significantly different; B and C represent the cell component analysis diagram and pseudo-time series analysis diagram of Huh-7 P and Huh-7 LR, respectively, and it can be seen that the simulated differentiation stages of the two cells are different; D represents the key gene expression difference diagram of Huh-7 P and Huh-7 LR, and it can be seen that Huh-7 P is more inclined to tumor maturity, while Huh-7 LR is more inclined to tumor stemness, metabolic transformation, metastasis, etc., and it can be seen that the two cells are significantly different. From the above results, it can be seen that compared with the original cell line Huh-7 P, the resistant cell line Huh7 LR has undergone a fundamental change, and the resistant cell line Huh7 LR is produced by long-term induction and pressure-induced by systemic therapeutic drugs (lenvatinib) that do not contain active aldehyde groups. Its single-cell sequencing results will also be significantly different from those of resistant cells produced by long-term induction by systemic therapeutic drugs containing active aldehyde groups (such as mitomycin and epirubicin), which means that there may also be obvious differences between the two in gene expression, cell signaling, metabolic pathways, epigenetics, morphology and phenotype.
[0059] (1.3) Identification of drug sensitivity of drug-resistant hepatocellular carcinoma cell models
[0060] In order to identify the drug sensitivity of the HCC resistant cell model, the CCK-8 assay and 3D cell spheroid probe staining assay were used in this experiment to identify the resistance of the two HCC resistant cell models (Huh7 LR and Huh7 SR) constructed in the above experiment (1.1) to a variety of drugs without active aldehyde groups (lenvatinib, sorafenib, regorafenib, gefitinib, lapatinib, fluorouracil, irinotecan and oxaliplatin) from two dimensional levels (two-dimensional and three-dimensional levels). The specific operations include the following:
[0061] (1.3.1) CCK-8 experiment:
[0062] 1) Inoculate the complete medium cell suspension of the original strain cells / drug-resistant strain cells (5000 cells / well) in a 96-well culture plate, about 100 μl per well;
[0063] 2) Place the culture plate in an incubator and culture for 48 hours (37°C, 5% CO 2 );
[0064] 3) Add drugs of gradient concentration to each well of the culture plate (targeted / chemotherapeutic drugs: lenvatinib, sorafenib, regorafenib, gefitinib, lapatinib, fluorouracil, irinotecan or oxaliplatin. The gradient concentrations are: 0, 1, 2, 4, 8, 16, 32, 64, 128 μM), and pay attention to setting the background wells;
[0065] 4) Place the culture plate in an incubator and incubate for 48 hours;
[0066] 5) Without changing the culture medium, add 10 μl of CCK-8 solution (Biyuntian, C0038) directly to each well, and avoid generating bubbles during the addition process;
[0067] 6) Place the culture plate in an incubator and incubate for 4 hours;
[0068] 7) Measure the absorbance at 450 nm using a multifunctional microplate reader.
[0069] During the experiment, at least 3 replicate wells were set for each gradient. The formula for calculating cell activity = (absorbance of experimental well - absorbance of background well) / (absorbance of control well - absorbance of background well).
[0070] like Figure 3 As shown, panel A shows the sensitivity curve of the original cell line and the drug-resistant cell line to lenvatinib and the calculated IC 50 Figure 2 shows the sensitivity curves of the original cell line and the drug-resistant cell line to sorafenib evaluated by CCK-8 assay and the calculated IC 50 The results showed that after the application of lenvatinib and sorafenib, the IC 50 There was a significant difference (p<0.001), lenvatinib: IC 50-Huh-7 P :13.02±0.73;IC 50-Huh-7 LR :50.61±4.62;Sorafenib:IC 50-Huh-7 P :6.78±0.13;IC 50-Huh-7 SR :16.70±1.15; indicating that the established drug-resistant cell line has good drug resistance. In addition, according to the results shown, it can also be found that the lenvatinib-resistant cell line Huh-7 LR is also resistant to sorafenib: IC 50 Huh-7 LR(索拉非尼) :21.06±0.66; Sorafenib-resistant cell line Huh-7 SR also showed resistance to lenvatinib: IC 50 Huh-7 SR(仑伐替尼) : 33.52±2.10; The results indicate that the hepatocellular carcinoma resistant cell model constructed in this embodiment is cross-resistant to both first-line targeted drugs, and both resistant cell models can be used for sensitivity identification of anti-liver cancer drugs that do not contain active aldehyde groups or can be used for screening anti-liver cancer drugs that do not contain active aldehyde groups that are sensitive to resistant cells.
[0071] The experiment also tested the resistance of the HCC resistant cell model constructed in this example to three common clinical targeted drugs - tyrosine kinase inhibitors (regorafenib, gefitinib and lapatinib, all purchased from MedChemExpress), and three common clinical chemotherapeutic drugs (fluorouracil, irinotecan and oxaliplatin, all purchased from MedChemExpress). The results showed that: Regorafenib: IC 50 Huh-7 P :6.40±0.24;IC 50 Huh-7 LR :8.53±0.59;IC 50 Huh-7 SR :10.31±0.40(IC of the original strain cells and the two drug-resistant strain cells 50 There is a significant difference). Gefitinib: IC 50 Huh-7 P :13.78±0.55;IC 50 Huh-7 LR :25.37±2.70;IC 50 Huh-7 SR :22.43±1.37 (IC of the original strain cells and the two drug-resistant strain cells 50 Lapatinib: IC 50 Huh-7 P :14.13±0.51;IC 50 Huh-7 LR :18.78±0.75;IC 50 Huh-7 SR :25.47±1.15(IC of the original strain cells and the two drug-resistant strain cells 50 Fluorouracil: IC 50 Huh-7 P :25.19±1.64;IC 50 Huh-7 LR :42.74±3.58;IC 50 Huh-7 SR :37.31±2.61(IC of the original strain cells and the two drug-resistant strain cells 50 Irinotecan: IC 50 Huh-7 P :24.54±1.44;IC 50 Huh-7 LR :22.00±1.43;IC 50 Huh-7 SR :40.76±3.72(IC of original strain cells and drug-resistant strain cells Huh-7 SR 50 Oxaliplatin: IC 50 Huh-7 P :39.98±1.60;IC 50 Huh-7 LR :59.25±4.59;IC 50 Huh-7 SR :79.75±4.39 (IC of the original strain cells and the two drug-resistant strain cells 50 The obtained cell survival rates were organized into a heat map, and the results are shown in Figure 4 As shown, it can be clearly seen that compared with the original cell line Huh-7 P, the two resistant cell lines basically show resistance to the above 6 targeted / chemotherapeutic drugs.
[0072] (1.3.2) 3D cell spheroid probe staining experiment
[0073] 1) 3D cell spheroid preparation and drug treatment
[0074] 1% w / v agarose solution (heated to 100°C in a microwave oven) was injected into a 96-well plate with a spray gun, 50 μl / well. After cooling to room temperature, a smooth and ultra-low adsorption groove was formed in the well plate. 100 μl of complete culture medium containing 700 original strain cells / drug-resistant strain cells was added to each well and cultured for 1 week to form 3D cell spheres. Then, the corresponding drug IC of the original strain cells obtained in the above experiment (1.2.1) was used 50 (i.e., the corresponding drug IC 50-Huh-7 P ) is used to process 3D cell spheroids (hereinafter also referred to as 3D microtissues), and the state of cells can be clearly observed by cell live / dead probe staining, and the dead cells in the 3D microtissue spheroids can be counted.
[0075] 2) Cell live-dead probe staining protocol
[0076] ① Prepare live cell (calcein-AM), dead cell (ethidium homodimer-1, EthD-1) staining probes and cell nucleus staining reagent (Hoechst 33342) and dilute them to 2× working concentration in ordinary DMEM culture medium.
[0077] ② Collect enough replicates (5-10) of cell spheres into a confocal glass-bottom 96-well plate, add 2× probe solution using the half-dilution method, incubate at 37°C for 40 min, and detect Alex 488 (live - green fluorescence), Alex 568 (dead - orange fluorescence), and Hoechst 33342 (nuclear fluorescence) channels using a high-content analyzer.
[0078] The results are as follows Figure 5 As shown, A shows the live / dead probe staining status of 3D microtissues after the application of targeted / chemotherapeutic drugs, and B shows the results of counting and statistics of fluorescently stained dead cells. It can be seen that the 3D microtissue spheroids formed by resistant cells are also resistant to targeted / chemotherapeutic drugs. Compared with the 3D microtissues formed by the self-assembly of the original cells, the resistant group has fewer dead cells. Figure 6 The statistical results of cell mortality after 3D cell spheroids were treated with lenvatinib or sorafenib were also exemplified. It was also obvious that compared with the 3D microtissues formed by self-assembly of the original strain cells, the cell mortality rate in the 3D microtissue spheroids formed by the resistant strain cells was significantly reduced, indicating that the constructed resistant strain cell models all have a high level of drug resistance.
[0079] In order to simulate the clinical drug combination application, several drug combinations were further tested in this example, including: lenvatinib / or sorafenib (corresponding drug IC 50-Huh-7 P ) were respectively compared with fluorouracil, irinotecan and oxaliplatin (the corresponding drugs IC 50-Huh-7 P ) combined application. The results of cell activity detection are as follows Figure 7 As shown, compared with the original strain cells, the tolerance of the resistant strain cells to the above combined drugs is significantly enhanced.
[0080] Example 2: Detection of aldose reductase levels in original strain cells and drug-resistant strain cells
[0081] This embodiment detects the aldose reductase levels in the original strain cells and the resistant strain cells, the 3D cell spheres formed by the original strain cells and the resistant strain cells, and the tissues from the liver cancer patients (including 15 liver cancer patients who did not use systemic treatment drugs and 15 patients who took drugs for a long time (>3 months) (the drugs taken by these patients were lenvatinib, sorafenib, 5-fluorouracil or oxaliplatin)) by immunofluorescence staining, HE and immunohistochemistry staining, and protein immunoblotting experiments.
[0082] (2.1) Immunofluorescence staining
[0083] (1) Sample type and preliminary processing:
[0084] ①2D cells: The original strain cells or drug-resistant strain cells were inoculated in a black glass-bottom 96-well plate / confocal dish at an appropriate ratio. After growing to an appropriate ratio and concentration, they were washed 3 times with PBS, fixed with 4% paraformaldehyde at room temperature for 20 minutes, washed 3 times with PBS, incubated with 0.125% Triton X-100 solution at room temperature for 20 minutes to break the membrane, and washed 3 times with PBS for later use.
[0085] ② 3D microtissue spheroids (obtained in (1.2.2) of Example 1): 5-8 spheroids were collected in a black glass-bottom 96-well plate, washed, fixed, and membrane-broken by half-fluid exchange for later use.
[0086] ③ Paraffin sections: dewaxing, hydration steps are the same as HE staining (as shown below), histochemical circle and blocking of endogenous catalase are the same as immunohistochemical staining, rinsed 3 times with PBS, incubated with 0.125% Triton X-100 solution at room temperature for 30 minutes to break the membrane, rinsed 3 times with PBS, and set aside.
[0087] (2) 10% blocking serum (blocking goat serum (Solarbio)), blocking at room temperature for 1 hour.
[0088] (3) 10% blocking serum was used as the diluent for preparing the primary antibody, i.e., AKR1B1 antibody (Abcam), and incubated overnight at 4°C. Note that the operation of 3D microtissue spheroids adopts the half-medium replacement method.
[0089] (4) The next day, the sections were rewarmed at room temperature for 1 hour, the primary antibody was washed with PBS, and then incubated with fluorescent secondary antibodies of the corresponding species, i.e., Alex647 fluorescently labeled anti-rabbit secondary antibodies (Thermo) diluted in PBS, at room temperature in the dark for 1 hour.
[0090] (5) After washing with PBS, nuclei were stained with DAPI (Biyuntian) for 20 minutes and then washed with PBS.
[0091] (6) The black glass-bottom 96-well plate was photographed with a high-content analyzer, the confocal dish was photographed with a super-resolution laser confocal microscope, and the sections were sealed with aqueous mounting media and photographed with a pathology section scanner.
[0092] (2.2) HE and immunohistochemical staining
[0093] (2.2.1) HE staining:
[0094]
[0095] (2.2.2) Immunohistochemical staining
[0096] ① Dewaxing and hydration: same as HE staining.
[0097] ② Antigen repair: Place the slices in sodium citrate repair solution and boil them in a microwave oven on medium heat for 10 minutes. Be careful not to boil them dry, then cool naturally at room temperature.
[0098] ③ Wash 3 times with TBS, draw the tissue with a tissue pen, and wash with 3% H 2 O 2 To remove endogenous peroxidase, incubate at room temperature for 10 minutes.
[0099] ④ Wash 3 times with TBS and block with horse serum diluted in the kit for 1 hour
[0100] ⑤ Wash 3 times with TBS, add Avidin solution, and leave at room temperature for 15 minutes; wash 3 times with TBS, add Biotin solution, and leave at room temperature for 15 minutes.
[0101] ⑥ Wash 3 times with TBS, dilute the primary antibody (AKR1B1 antibody (Abcam)) with blocking solution, add the primary antibody, and place in a humidified box at 4°C overnight.
[0102] ⑦ After equilibration at room temperature for 1 hour, wash three times with TBS, add secondary antibody, i.e. horse anti-rabbit / mouse IgG (H+L) (Vector Laboratories), and incubate at room temperature for 1 hour.
[0103] ⑧Wash 3 times with TBS and add staining reagent. Since the color develops quickly, it needs to be observed immediately and rinse with running water immediately.
[0104] ⑨ Stain the nucleus with hematoxylin for 3 minutes, rinse the slices with clean water, and air-dry; then dehydrate and seal the slices (same as HE staining).
[0105] (2.3) Protein immunoblotting
[0106] (2.3.1) Protein sample preparation
[0107] Protein extraction of cell samples: cells (original strain cells or drug-resistant strain cells) were inoculated in 6-well plates. When the cells grew to 90%, they were washed with cold PBS and 150 μl of prepared cell lysis buffer (RIPA + protease inhibitor PMSF + phosphatase inhibitor) was added. The cells were scraped off on an ice plate with a cell scraper and placed in EP tubes. They were lysed at 4°C for 30 minutes, ultrasonicated in an ice water bath for 3 minutes, and centrifuged at 12,000 rpm at 4°C for 15 minutes. The supernatant was taken out. It was better to have less than more. Do not aspirate the precipitate. The protein concentration was determined. 5× protein loading buffer was added and the cells were incubated at 95°C for 10 minutes. The cells were frozen at -20°C for later use.
[0108] (2.3.2) Preparation of gel electrophoresis plate
[0109] Assemble the glass plate (pay attention to leak detection), first prepare 10% separation gel (Table 1) in sequence, add it into the glass plate immediately, add pure water sealing liquid to a certain height, wait for 20 minutes at room temperature, then prepare concentration gel (Table 1) in sequence, add it into the glass plate immediately, insert the lane comb (1.0mm specification), and wait for about 30 minutes.
[0110] Table 1: Gel electrophoresis recipe
[0111]
[0112] (2.3.3) Sample loading and electrophoresis
[0113] Prepare 1× electrophoresis solution according to the formula in Table 2, store at room temperature away from light, and reuse 3 times.
[0114] Table 2: Electrophoresis fluid formula
[0115] Reagents Addition amount Pure water 2L Tris 6g Glycine 37.6g SDS 2g
[0116] (2.3.4) Transfer
[0117] After the electrophoresis is finished, prepare the tray, pour in the transfer solution (formula: 1L pure water, 30.26g Tris, 144.1g glycine), arrange the transfer clip, sponge sheet, filter paper (sandwich clip: black glue and white film), soak in the transfer solution, take another small dish, put in anhydrous methanol, prepare the transfer membrane (PVDF membrane) and activate it in methanol for 5 minutes. Prepare to cut the gel, pry open the thin glass plate, cut it into the appropriate size (with Marker) according to the indicated position of the Marker, put it on the filter paper, and then stick the marked transfer membrane, and be careful not to have bubbles.
[0118] After assembly, place the transfer apparatus according to the direction of the electrode, place the whole in an ice water bath, and set the transfer conditions: constant current: 0.28A, (maximum KDa+15) minutes.
[0119] (2.3.5) Closure
[0120] Prepare blocking solution (5% skim milk powder for blocking): 1g milk powder is dissolved in TBST (1L TBS + 1ml Tween-20) to 20ml, and the PVDF membrane is placed in the blocking solution and blocked at room temperature for 2 hours. After blocking, wash with TBST for 10 minutes, a total of 3 times.
[0121] (2.3.6) Primary antibody incubation
[0122] The PVDF membrane was immersed in the primary antibody (AKR1B1 (target protein) (Abcam) or β-actin (internal reference protein) (Servicebio) as the primary antibody) and incubated at 4°C in a shaking incubator overnight.
[0123] (2.3.7) Secondary antibody incubation
[0124] The next day, the PVDF membrane was immersed in the secondary antibody, namely horseradish peroxidase-labeled goat anti-rabbit secondary antibody (Biyuntian), and incubated at room temperature for 2 hours.
[0125] (2.3.8) Development
[0126] Prepare the luminescent liquid: ECL luminescent liquid reagent A+B, the ratio is 1:1 (prepare before use), prepare a dark box to fully soak the PVDF membrane, so that the luminescent liquid is distributed all over the membrane, develop it with a chemical imager, and save the original picture with markers and marks.
[0127] The results are as follows Figure 8As shown, A shows the immunofluorescence detection results of the original strain cells, drug-resistant strain cells and 3D microtissues formed by these cells, B shows the protein immunoblotting quantitative detection results of AKR1B1 in the original strain cells and drug-resistant strain cells, and C shows the immunofluorescence and immunohistochemical staining results of tissues from liver cancer patients. The results showed that at the immunofluorescence level of 2D cells and 3D microtissues, the expression level of AKR1B1 in drug-resistant strain cells was significantly higher than that in the original strain cells (Huh-7 LR / Huh-7 P p<0.0001; Huh-7 SR / Huh-7 P p<0.0001). At the same time, the protein of 2D cells was extracted for quantitative immunoblotting, and the results were basically consistent with the above immunofluorescence staining. Furthermore, tissues from patients with clinically derived hepatocellular carcinoma who had continuously used systemic treatment drugs for more than 3 months and those who had never used systemic treatment drugs were selected for immunofluorescence and immunohistochemistry staining. The results showed that the expression level of AKR1B1 in the drug-treated group was significantly increased compared with the non-drug group (p<0.0001).
[0128] In order to clarify the relationship between AKR1B1 expression level and drug resistance, we further detected the expression level of AKR1B1 during the establishment of drug-resistant cells. Fig. 9 As shown, panels A and B respectively represent the relationship between the establishment of lenvatinib and sorafenib resistance and the expression of AKR1B1, and panel C represents the correlation analysis between the resistance of drug-resistant cells and the expression of AKR1B1 (S in the figure 0 -S 3 Indicates: [IC 50 Huh-7 LR (S 0 :13.020μM; S 1 :19.150μM; S 2 :36.400μM; S 3 :50.610μM); IC 50 Huh-7 SR (S 0 :6.768μM; S 1 :9.456μM; S 2 :13.530μM; S 3 :19.460μM)]), it is obvious that with the increase of drug resistance of drug-resistant cells, the expression of AKR1B1 also increases. The high correlation analysis between the two fully proves that the expression level of AKR1B1 is closely related to the level of drug resistance (Huh-7 LR: p<0.0178; Huh-7SR: p<0.0128).
[0129] Example 3: Metabolic phenotype evaluation of original cell lines and drug-resistant cell lines and identification of key targets
[0130] This example evaluates the metabolic phenotype of the original cell line and the drug-resistant cell line constructed in Example 1 by detecting the triglyceride content, NADH content, NADPH content, fatty acid uptake capacity (stimulated Raman scattering imaging and fluorescent probe tracer fatty acid uptake detection), fatty acid β-oxidation rate, and Seahorse cell energy metabolism analysis (including glycolysis detection and ATP rate detection) of the original cell line and the drug-resistant cell line.
[0131] (3.1) Triglyceride content
[0132] The factors directly related to tumor growth are metabolic factors, so in this experiment, the key indicator of lipid metabolism energy supply in the original cell line Huh-7 P and the drug-resistant cell line Huh-7 LR was detected - the content of triglycerides (using a triglyceride detection kit, Nanjing Jiancheng). The results are as follows Fig.10 As shown, compared with the original strain cells, the triglyceride content of the resistant strain cells was significantly increased (p<0.01).
[0133] (3.2) NADH and NADPH content
[0134] NAD + It is the main hydrogen receptor for cellular glycolysis and tricarboxylic acid cycle. The generated NADH transfers electrons to oxygen through the electron transport chain to generate ATP and reactive oxygen species. At the same time, NADH is regenerated into NAD. + , NAD + The content of NADPH and NADP can be used to evaluate the metabolic level of cell glycolysis and tricarboxylic acid cycle. + The content of NAD is closely related to the pentose phosphate pathway, biosynthesis, biotransformation and antioxidant response in the cell metabolism process. In this experiment, the NAD content of the original cell Huh-7 P and the drug-resistant cell Huh-7 LR and Huh-7 SR was detected. + The content of NADH and NADPH and NADP + The results are as follows Fig.11 As shown, NAD + The levels of NADH were significantly higher than those of the original strain cells (Huh-7 LR / Huh-7P p<0.0001; Huh-7 SR / Huh-7P p<0.0001) (see Fig.11 A), and the NADP + The levels of NADPH were also significantly higher than those of the original strain cells (Huh-7 LR / Huh-7 P p < 0.001; Huh-7 SR / Huh-7 P p < 0.0001) (see Fig.11Middle B). The detection of the contents of two key enzymes that characterize energy and biosynthesis metabolism levels showed that the metabolic state of the drug-resistant strain cells was more vigorous than that of the original strain cells.
[0135] (3.3) Glycolytic metabolism
[0136] In this experiment, the Seahorse energy metabolism analyzer was used to detect the glycolysis level of the original cell line Huh-7 P and the drug-resistant cell lines Huh-7 LR and Huh-7 SR. Fig.12 As shown in the figure, the glycolysis level (Huh-7 LR / Huh-7P p<0.01; Huh-7 SR / Huh-7 P p<0.05), capacity (Huh-7 LR / Huh-7 P p<0.01; Huh-7 SR / Huh-7 P p<0.01) and reserve (Huh-7 LR / Huh-7 P p<0.05; Huh-7 SR / Huh-7 P p<0.01) of the resistant strain cells were higher than those of the original strain cells (see Fig.12 A in the middle), indicating that glycolysis is an important way for drug-resistant cells to obtain energy. In this experiment, the energy source of the cells was also detected, and it was found that compared with the original strain cells, the glycolysis-derived ATP energy supply accounted for a higher proportion in the drug-resistant strain cells (Huh-7 LR / Huh-7 P p<0.001; Huh-7 SR / Huh-7 P p<0.05) (see Fig.12 The above results show that the glycolysis process of the drug-resistant cells is more vigorous than that of the original cells, and it is the main source of energy for the drug-resistant cells.
[0137] (3.4) Fatty acid uptake capacity
[0138] 3.4.1. Stimulated Raman scattering method
[0139] The experiment used stimulated Raman scattering (SRS) to detect deuterated palmitic acid. 31-PA) probe was used to observe the uptake of lipids by cells. The results showed that the uptake of lipids by resistant cells was significantly higher than that by original cells (Huh-7 LR / Huh-7 P p<0.01; Huh-7 SR / Huh-7 P p<0.0001). At the same time, the analysis of the proportion of uptake of lipids to total lipids also showed that the uptake of lipids by resistant cells was significantly higher than that by original cells (Huh-7 LR / Huh-7 P p<0.05; Huh-7SR / Huh-7 P p<0.05). In addition, lipid molecular component analysis-unsaturation evaluation was also performed in this experiment. The results showed that although resistant cells took up a large amount of saturated fatty acids, their unsaturation level was still lower than that of original cells (Huh-7 LR / Huh-7 P p<0.01; Huh-7 SR / Huh-7 P p<0.05). Highly unsaturated fatty acids can easily lead to lipid peroxidation and damage cells. It is speculated that the implementation of this strategy by resistant cells is beneficial to the protection of the cells themselves.
[0140] 3.4.2. Tracer probe combined with high-content fluorescence imaging system method
[0141] The experiment continued to use the real-time fatty acid uptake tracer probe in conjunction with the high-content fluorescence imaging system to record the fatty acid uptake process every 15 minutes for 7.5 hours. Eight representative time points were selected for display. The results are as follows: Fig.13 As shown, the fatty acid uptake of resistant cells was significantly higher than that of the original strain cells, which was consistent with the stimulated Raman scattering vibration imaging detection.
[0142] 3.5. Fatty acid β-oxidation level
[0143] This experiment was designed to evaluate the level of fatty acid β-oxidation energy supply in the original cell line Huh-7 P and the drug-resistant cell lines Huh-7 LR and Huh-7 SR. Fig.14 As shown, the level of fatty acid β-oxidation in resistant cells was significantly increased compared with that in the original strain cells (Huh-7 LR / Huh-7 P p<0.0001; Huh-7 SR / Huh-7 P p<0.001).
[0144] The metabolic phenotype test results of 3.1-3.5 above all indicate that drug-resistant cells have more vigorous metabolic processes, which provide a guarantee for the survival and proliferation of cells in the drug environment.
[0145] In this embodiment, in order to find out the reasons and results of the transformation of the original strain cells into the drug-resistant strain cells, the transcriptomes of the original strain and the drug-resistant strain cells were sequenced, and the results showed that the transcriptome level of Huh-7 LR / SR drug-resistant strain cells had undergone significant changes, and most genes were upregulated. Further, GSEA analysis was used to find that the two drug-resistant strains of cells were significantly upregulated in fatty acid metabolism (Huh-7 LR / Huh-7 P p=0.002; Huh-7 SR / Huh-7 P p=0.007) that reflects the metabolic capacity of cells and epithelial-mesenchymal transformation (Huh-7 LR / Huh-7 P p<0.001; Huh-7 SR / Huh-7 P p<0.001) that reflects the invasive ability of cells. By using Cytoscape software (selected parameters: Degree Cutoff: 2; Haircut√; Node Density Cutoff: 0.1; Node Score Cutoff: 0.2; K-Core: 2; Max.Depth: 100), the interactions between these up-regulated genes and proteins were analyzed, and the results showed that these genes focused on lipid metabolism, cell growth, and polyol and glutathione metabolic pathways. At the same time, by performing KEGG and GO pathway enrichment analysis on these up-regulated genes, it was found that the up-regulated genes of drug-resistant cells compared with those of the original strain cells were more focused on metabolic pathways, extracellular matrix structure, lipid metabolism and other processes.
[0146] Based on the above results, in this example, metabolomics detection was also performed on the original strain and the drug-resistant strain cells. The results showed that compared with the original strain cells, the Huh-7 LR drug-resistant strain cells showed significant differences in amino acid, fatty acid, carbohydrate and nucleotide metabolism. 13 C-labeled glucose was used to track sugar metabolism by metabolic flux to reflect the activity of metabolic pathways. The results showed that in several major metabolic pathways, such as glycolysis, pentose phosphate pathway and tricarboxylic acid cycle, drug-resistant cells were more active than the original strain cells, which was closely related to the energy and substrate required for the growth of drug-resistant cells. By combining metabolomics detection with metabolic flux detection, it was found that the glutathione pathway, glycolysis pathway and polyol and fructose metabolic pathways of drug-resistant cells were most active compared with the original strain cells. These classic metabolic pathways also suggest that drug-resistant cells have stronger growth energy supply and self-protection capabilities.
[0147] 3.6. Combined transcriptomics and metabolomics to identify key targets
[0148] In this experiment, representative pathways enriched by metabolites identified by metabolomics were selected, and all upregulated enzymes in the pathways were screened in combination with transcriptomics. Finally, AKR1B1, which is closely related to fructose metabolism, pentose glucuronide conversion, glutathione metabolism, and triglyceride metabolism, was identified as a key enzyme target. Fig.15 shown.
[0149] 3.7. Knockdown of AKR1B1 expression affects the metabolic phenotype of drug-resistant cells
[0150] 3.7.1. Construction of AKR1B1 knockdown cell line of drug-resistant cells
[0151] In this experiment, the AKR1B1 gene in the two drug-resistant cell lines (Huh-7 LR and Huh-7SR) constructed in Example 1 was knocked down by lentiviral transfection, and a stable drug-resistant cell AKR1B1 knockdown cell line was successfully constructed (three drug-resistant cell AKR1B1 knockdown cell lines were obtained for each drug-resistant cell line, named Huh-7 LR: sh-AKR1B1-1, sh-AKR1B1-2, sh-AKR1B1-3; Huh-7 SR: sh-AKR1B1-1, sh-AKR1B1-2, sh-AKR1B1-3). Fig.16 As shown (sh-NC in the figure represents Negative Control, i.e., negative control), wherein panel A shows the detection results of AKR1B1 protein levels in the obtained drug-resistant cell AKR1B1 knockdown cell line, and panel B represents the AKR1B1 gene transfection efficiency displayed by GFP fluorescence.
[0152] 3.7.2. Metabolic phenotype of AKR1B1 knockdown cell lines in drug-resistant cells
[0153] This experiment was conducted according to the method described in the CCK-8 experiment in Example 1 (1.2.1) to detect the drug resistance phenotype of Huh-7LR: sh-AKR1B1-1 and Huh-7SR: sh-AKR1B1-1 constructed in step 3.7.1 above. Fig.17 As shown in Figure 2, it can be seen that after AKR1B1 knockdown, the intracellular triglyceride level was significantly decreased (Huh-7 LR sh-AKR1B1 / Huh-7LR sh-NC p<0.01; Huh-7 SR sh-AKR1B1 / Huh-7 SR sh-NC p<0.05) (see Fig.17From the perspective of lipid droplet levels, it was found that compared with cells without AKR1B1 knockdown, the number of intracellular lipid droplets was significantly reduced after knockdown (Huh-7LR sh-AKR1B1 / Huh-7 LR sh-NC p<0.05; Huh-7 SR sh-AKR1B1 / Huh-7 SR shNC p<0.01) (see Fig.17 In terms of fatty acid β-oxidation level, the β-oxidation level of resistant cells was significantly reduced after AKR1B1 knockdown (Huh-7 LR sh-AKR1B1 / Huh-7 LR sh-NC p<0.001; Huh-7 SR sh-AKR1B1 / Huh-7 SRsh-NC p<0.01) (see Fig.17 (middle C).
[0154] In addition, in this experiment, in order to explore the effect of AKR1B1 on the glutathione metabolic pathway of drug-resistant cells, the inventors first detected the basal level of the glutathione metabolic pathway and found that the resistant cells were significantly higher than the original cells (Huh-7 LR / Huh-7 P p<0.0001; Huh-7 SR / Huh-7 P p<0.0001). In addition, the detection of reactive oxygen species found that the original cells were more responsive to drugs and more prone to reactive oxygen accumulation. The above results show that drug-resistant cells have a strong self-protection mechanism, and the upregulated glutathione level and the downregulated reactive oxygen level are both conducive to cell survival. After knocking down AKR1B1, the glutathione metabolic pathway of the drug-resistant cells was inhibited and the protein expression levels of key genes were reduced. At the same time, in the cells with AKR1B1 knocked down, the glutathione level decreased (Huh-7 LR sh-AKR1B1 / Huh-7 LR sh-NC p<0.0001; Huh-7 SR sh-AKR1B1 / Huh-7 SR sh-NC p<0.0001), and the reactive oxygen level increased after the action of the drug (Huh-7 LR sh-AKR1B1 / Huh-7 LR sh-NC p<0.0001; Huh-7 SR sh-AKR1B1 / Huh-7 SR sh-NCp<0.01).
[0155] The above results show that AKR1B1 not only promotes the polyol and fructose metabolic pathways, ultimately pointing to the synthesis and oxidation of triglycerides, but also significantly affects glutathione metabolism, thereby jointly maintaining the survival and growth of drug-resistant cells from the two aspects of cell energy supply and cell protection. In addition, it can also be shown that AKR1B1 is closely related to the activity of the glucose and lipid metabolic pathways and glutathione metabolic pathways of liver cancer cells. Therefore, AKR1B1 can be used as an intervention target to regulate the activity of the glucose and lipid metabolic pathways and glutathione metabolic pathways of liver cancer cells. For example, by inhibiting the expression of AKR1B1, the activity of the glucose and lipid metabolic pathways and glutathione metabolic pathways of liver cancer cells can be reduced, and by enhancing the expression of AKR1B1 (or overexpressing AKR1B1), the activity of the glucose and lipid metabolic pathways and glutathione metabolic pathways of liver cancer cells can be increased.
[0156] Example 4: Verification of the effect of aldose reductase on drug sensitivity using animal models
[0157] (4.1) Animal model construction
[0158] In this experiment, BALB / C nude mice (male, 6 weeks old, obtained from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.) were used to construct the original strain / lenvatinib-resistant strain animal model, including the following operations (all animal experiments were performed in accordance with the experimental protocol approved by Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. (No.: PA23062801)):
[0159] ① Add the cell suspension into cold Matrigel in equal proportions, 7×10 6 Cells / 150 μl / mouse, implanted subcutaneously on the back of mice, 5 mice per group;
[0160] ② When the diameter of the subcutaneous tumor tissue grew to 6 mm, the animals were randomly divided into 4 groups: control group - solvent group (5‰ sodium carboxymethyl cellulose solution) and experimental group - lenvatinib group (lenvatinib 5 mg / kg / d), and the drugs were administered by gavage.
[0161] ③Measure the weight and tumor volume of nude mice every other day. 3 ) is calculated as 1 / 2 × the longest meridian of the tumor × the shortest meridian of the tumor 2 .
[0162] ④ Two weeks after administration, samples were collected and then the tissues were cryopreserved, fixed and embedded.
[0163] The results are as follows Fig.18As shown, A shows the tumor tissue and mouse entity image of nude mice, B shows the tumor volume growth curve of nude mice, and C shows the statistical results of tumor weight of nude mice. It can be clearly seen that compared with the original cell tumor, the resistant cell tumor showed better tolerance to the drug, which was manifested by larger tumor volume (p<0.0001) and heavier mass (p<0.0001). Fig.19 The results of protein immunoblotting experiments on the expression of aldose reductase in tumor-bearing tissues from two animal models are shown. It can be seen that the expression level of aldose reductase in tumor-bearing tissues formed by resistant cell lines is significantly higher than that in tumor-bearing tissues formed by original cell lines.
[0164] Example 5: Detection of the expression level of aldose reductase in the serum of patients with liver cancer
[0165] This example uses the Elisa method to detect the expression level of aldose reductase in the serum of liver cancer patients (liver cancer patients who have not used systemic treatment drugs (36 cases in total) and patients who have been taking drugs for a long time (>3 months) (28 cases in total, these patients took drugs such as lenvatinib, sorafenib, 5-fluorouracil or oxaliplatin)), which specifically includes the following operations:
[0166] (5.1) Sample collection and storage
[0167] ① Serum: Place the whole blood sample at room temperature for 2 hours. Centrifuge at 1000g for 20 minutes, take the supernatant, and store it in aliquots at -80℃ for later use.
[0168] ②Cell culture supernatant: Collect the supernatant, centrifuge at 2500 rpm for 5 minutes at 2-8°C, collect the clarified supernatant, and freeze it at -80°C for later use.
[0169] (5.2) Reagent preparation
[0170] ①Before use, place all reagents and samples at room temperature for 20 minutes to equilibrate.
[0171] ② Prepare washing buffer solution, dilute the concentrated washing solution 25 times with deionized water and mix well.
[0172] ③ Add 1 ml of sample diluent to the standard tube and leave it at room temperature for 10 minutes. Take another 7 EP tubes and mark them as 1 / 2, 1 / 4, 1 / 8, 1 / 16, 1 / 32, 1 / 64 and a blank tube. Add 0.3 ml of volume in sequence and mix until 1 / 64. Only add the diluent to the blank tube.
[0173] ④ Prepare the biotinylated antibody working solution 1 hour in advance. The total volume of the working solution (need to consider the actual operation loss) = 0.1 ml / well × number of wells. Dilute the biotinylated antibody with antibody dilution buffer (1:100) and mix thoroughly.
[0174] ⑤ Prepare HRP-streptavidin conjugate (SABC) half an hour in advance. The total volume of working solution (need to consider the actual operation loss) = 0.1mI / well × number of wells. Dilute SABC with SABC diluent (1:100) and mix thoroughly.
[0175] (5.3) Determination
[0176] ① Add 100 μl of standard and sample to each well, cover with film, and incubate at 37°C for 90 minutes.
[0177] ②Wash the plate twice with washing buffer.
[0178] ③Add 100 μl of biotin-labeled antibody working solution to each well, cover with film, and incubate at 37°C for 1 hour.
[0179] ④Wash the plate 3 times with washing buffer.
[0180] ⑤ Add 100 μl SABC working solution to each well, cover with film, and incubate at 37°C for half an hour.
[0181] ⑥Wash the plate 5 times with washing buffer.
[0182] ⑦ Equilibrate the TMB substrate at 37°C for half an hour in advance, add 90 μl of TMB substrate solution to each well, cover with film, incubate at 37°C for 20 minutes, away from light. When a clear blue gradient appears in the standard well, terminate the reaction.
[0183] ⑧Add 50μl of stop solution to each well, and the color of the solution will change from blue to yellow.
[0184] ⑨ The absorbance at 450nm was measured by a multifunctional microplate reader. According to the standard curve, the target concentration of the sample was calculated.
[0185] The results are as follows Fig. 20As shown, it can be seen that the AKR1B1 content in the serum of patients with continuous medication is significantly increased (p<0.05). Therefore, the content of AKR1B1 in the serum of patients treated with drugs can be detected to predict whether they are resistant. According to the test results of this embodiment, among the 36 untreated liver cancer patients, 31 cases (accounting for 86.1%) had serum AKR1B1 concentrations of <1.40ng / ml, and 5 cases (accounting for 13.9%) were ≥1.40ng / ml. According to the results of the cell model, AKR1B1 is highly expressed in drug-resistant cells and almost not expressed in original cells. In addition, the AKR1B1 concentration in the serum of 28 patients with continuous medication (>3 months) has changed significantly compared with that of untreated patients, of which 18 cases (accounting for 64.3%) were ≥1.40ng / ml, and 10 cases (accounting for 35.7%) were <1.40ng / ml. Therefore, we can use the AKR1B1 concentration of 1.40 ng / ml as the reference prediction line for the baseline level. Among the 28 patients who have been taking the drug continuously (>3 months), it can be predicted that 18 patients with serum AKR1B1 concentration ≥1.40 ng / ml may develop drug resistance, while 10 patients with serum AKR1B1 concentration <1.40 ng / ml will not develop drug resistance. To summarize the above description, the criteria for predicting whether a patient will develop drug resistance to anti-liver cancer drugs that do not contain active aldehyde groups can be: when the concentration of AKR1B1 in the patient's serum is <1.4 ng / ml, it can be predicted that the patient will not develop drug resistance; when the concentration of AKR1B1 in the patient's serum is ≥1.4 ng / ml, it can be predicted that the patient will develop drug resistance.
[0186] Example 6: Knockdown of AKR1B1 expression affects drug sensitivity of drug-resistant cells
[0187] This example detects the drug-resistant phenotype of Huh-7 LR: sh-AKR1B1-1 and Huh-7 SR: sh-AKR1B1-1 constructed in 3.7.1 of the above Example 3 according to the method described in the CCK-8 experiment in Example 1 (1.2.1). The results are shown in FIG. Fig.21 As shown, A represents the sensitivity test results of Huh-7 LR: sh-AKR1B1-1 to lenvatinib, B represents the sensitivity test results of Huh-7 SR: sh-AKR1B1-1 to sorafenib, C represents the sensitivity heat map of Huh-7 LR: sh-AKR1B1-1 to various systemic therapeutic drugs, and D represents the sensitivity heat map of Huh-7 SR: sh-AKR1B1-1 to various systemic therapeutic drugs. Fig.21The results shown show that after AKR1B1 knockdown, the sensitivity of drug-resistant cells to the drugs used for construction (lenvatinib or sorafenib) increased significantly (Huh-7 LR p<0.0001; Huh-7 SR p<0.01). At the same time, the multidrug resistance reactivity heat map also shows that the sensitivity of drug-resistant cell AKR1B1 knockdown cell lines to a variety of targeted drugs and chemotherapeutic drugs (regorafenib, gefitinib, lapatinib, irinotecan, fluorouracil, oxaliplatin) is also significantly increased.
[0188] Example 7: Knockdown of AKR1B1 expression affects drug sensitivity in tumor-bearing animal models
[0189] This example uses the animal model construction method in Example 4 (4.1) to conduct a nude mouse in vivo tumor experiment using Huh-7LR: sh-AKR1B1-1 constructed in the above Example 3. When the diameter of the subcutaneous tumor tissue grows to 6 mm, the animals are randomly divided into 6 groups: blank-solvent group, negative control-solvent group, target knockdown-solvent group, and solvent (5‰ sodium carboxymethyl cellulose solution); blank-lenvatinib group, negative control-lenvatinib group, target knockdown-lenvatinib group are given lenvatinib (5 mg / kg / d), and the drug is administered by oral gavage every day. The body weight and tumor tissue volume of nude mice were measured every other day. The tumor tissue volume (mm 3 ) is calculated as 1 / 2 × the longest meridian of the tumor × the shortest meridian of the tumor 2 . Two weeks after administration, samples were collected and then cryopreserved, fixed and embedded.
[0190] The results are as follows Fig. 22 As shown, A shows the nude mouse tumor tissue and mouse entity, B shows the nude mouse tumor weight statistics, and C shows the nude mouse tumor volume growth curve. It can be clearly seen that after the application of lenvatinib, the tumor volume of the AKR1B1 knockdown group was significantly reduced, the tumor growth rate was significantly slowed down (p<0.0001), and the tumor mass was significantly reduced (p<0.0001). Fig.23 The results of protein immunoblotting experiments to detect the levels of key genes in the glutathione metabolic pathway in nude mouse tumor tissues show that when AKR1B1 was knocked down, the glutathione metabolic pathway was significantly inhibited.
[0191] Example 8: Effect of AKR1B1 targeted drug epalrestat on the growth of drug-resistant cells
[0192] This example uses an aldose reductase inhibitor, epalrestat, and detects the effect of epalrestat or its combination with anti-liver cancer drugs (lenvatinib or sorafenib) on the drug sensitivity of the two drug-resistant cell lines (Huh-7 LR and Huh-7 SR) constructed in Example 1 and the original cell line according to the method described in the CCK-8 experiment (1.2.1) in Example 1. The results are shown in FIG. Fig.24 As shown, panel A shows the cell survival curves of two drug-resistant cell lines (Huh-7 LR and Huh-7 SR) and the original cell line treated with epalrestat, and panel B shows the IC calculated based on the survival curve of panel A. 50 , C and D represent the combined effect test of epalrestat and lenvatinib or sorafenib. It can be seen that after treatment with epalrestat, the growth of resistant cells was significantly inhibited compared with the original cells (IC 50 Huh-7 P :85.010±1.008;IC 50 Huh-7 LR :53.960±0.978;IC 50 Huh-7 SR :67.220±0.994), and when used in combination, epalrestat and lenvatinib or sorafenib have good synergistic effects in inhibiting the growth of drug-resistant cells at multiple concentrations. The above results also show that when the drug-resistant cells are treated with epalrestat, an inhibitor of aldose reductase, their sensitivity to the constructed drugs (lenvatinib or sorafenib) is significantly enhanced.
[0193] Example 9: Effect of AKR1B1 inhibitor epalrestat on tumor growth
[0194] This example aims to explore the effect of AKR1B1 inhibitor epalrestat on tumor growth in animal models. The lenvatinib-resistant strain animal model constructed in Example 4 was treated with AKR1B1 inhibitor epalrestat, lenvatinib, or a combination of the two. Specifically, when the diameter of the subcutaneous tumor tissue grew to 6 mm, the animals were divided into 4 groups according to the principle of random allocation: the solvent group was given solvent (5‰ sodium carboxymethyl cellulose solution), the epalrestat group was given (50 mg / kg / d), the lenvatinib group was given (5 mg / kg / d), and the combination group was given (epalrestat 50 mg / kg / d + lenvatinib 5 mg / kg / d), and the administration was oral. The body weight and tumor tissue volume of nude mice were measured every other day. The tumor tissue volume (mm 3 ) is calculated as 1 / 2 × the longest meridian of the tumor × the shortest meridian of the tumor 2 . Two weeks after administration, samples were collected and then cryopreserved, fixed and embedded.
[0195] The results are as follows Fig.25As shown, A shows the tumor tissue and mouse entity of nude mice, B shows the volume growth curve of nude mice tumors, and C shows the statistical results of nude mice tumor weight. It can be clearly seen that compared with the use of epalrestat or lenvatinib alone, after combined use, the tumor volume was significantly reduced, the tumor growth was significantly slowed down (combination therapy / lenvatinib: p<0.0001; combination therapy / epalrestat: p<0.0001), and the tumor weight was significantly reduced (combination therapy / lenvatinib: p<0.01; combination therapy / epalrestat: p<0.001). In addition, according to Fig.25The results also show that the use of epalrestat alone did not reduce the volume and weight of the tumor. It is speculated that this may be related to the fact that epalrestat does not interfere with the angiogenesis of the tumor. The rich blood supply makes the interference of the indirect energy supply and protection of cells caused by the use of epalrestat alone almost negligible. However, when epalrestat is used in combination with lenvatinib, it can significantly reduce the volume and weight of the tumor and significantly slow down the growth of the tumor, showing a synergistic effect. This may be due to the blocking effect of lenvatinib on angiogenesis, which greatly highlights the role of epalrestat and finally presents a good combined application effect, and the combined application effect of the two exceeds the combined application effect of epalrestat and sorafenib. The above results show that the AKR1B1 inhibitor epalrestat has great clinical application potential. By combining it with lenvatinib, it can significantly improve the problem of drug resistance, and thus provide a more effective drug for treating liver cancer patients who are resistant to systemic treatment drugs for liver cancer. Although Han Chao (Han Chao. Study on the role of AKR1B10 in the early diagnosis of liver cancer and the regulation of HepG2 cell proliferation by its inhibitors [D]. China Medical University, 2018, hereinafter referred to as Document 1) has disclosed that the combined use of epalrestat and sorafenib can significantly improve the inhibition rate of sorafenib on HepG2 cell proliferation, it suggests that the combination of the two can synergistically improve the efficacy of sorafenib. However, the document 1 discloses the effect of epalrestat combined with sorafenib on non-resistant HepG2 cells (the IC50 value of sorafenib for its HepG2 cells disclosed in the document 1 is about 6 μmol / L (i.e., 6 μM)). Most studies have shown that the sensitivity of resistant HepG2 cells to drugs such as sorafenib is significantly reduced, just as the IC50 value of sorafenib for the resistant cell Huh-7 LR constructed by the present invention is about 21.06±0.66 μM, which is significantly higher than the IC50 value of sorafenib for the original cell Huh-7 P (6.78±0.13 μM). In addition, it can be seen from the single-cell sequencing results of 1.2 in the above Example 1 that the resistant cells have undergone a fundamental transformation compared with the original cells, and there are obvious differences between the two in terms of gene expression, cell signal transduction, metabolic pathways, epigenetics, morphology and phenotype. Therefore, although the combined use of epalrestat and sorafenib can improve the efficacy of sorafenib against non-resistant HepG2 cells, this does not mean that it can reverse the drug resistance of resistant cells, nor can it predict the efficacy of epalrestat and sorafenib disclosed in the above document 1 on resistant cells (especially when the above results have proved that the use of epalrestat alone does not reduce the volume and weight of the tumor), and it is even more impossible to predict the efficacy of the combination of the two on lenvatinib-resistant cells.
[0196] Finally, it should be noted that the above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art can still modify the technical solutions described in the aforementioned embodiments or replace some of the technical features therein by equivalents. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. Application of aldose reductase as a target in regulating the activity of glycolipid metabolic pathway and glutathione metabolic pathway in liver cancer cells.
2. Use of an agent for interfering with aldose reductase expression in the preparation of a drug for reversing the resistance of liver cancer patients to systemic liver cancer therapeutic drugs, wherein the systemic liver cancer therapeutic drug is an anti-liver cancer drug that does not contain an active aldehyde group.
3. The use according to claim 2, wherein the drug reverses the resistance of liver cancer patients to systemic treatment drugs for liver cancer by reducing the activity of the glycolipid metabolic pathway and the glutathione metabolic pathway in the liver cancer tissue or cells of the liver cancer patients.
4. Use of an agent for interfering with aldose reductase expression in the preparation of a drug for treating liver cancer patients resistant to systemic liver cancer treatment drugs, wherein the systemic liver cancer treatment drug is an anti-liver cancer drug that does not contain an active aldehyde group.
5. Use of an agent for interfering with aldose reductase expression in combination with an anti-liver cancer targeted drug in the preparation of a drug for treating liver cancer patients resistant to systemic liver cancer treatment drugs, wherein the systemic liver cancer treatment drug is an anti-liver cancer drug that does not contain an active aldehyde group; Preferably, the agent intervening in the expression of aldose reductase is Epalrestat, and the anti-liver cancer targeted drug is Lenvatinib.
6. The use according to any one of claims 2 to 5, wherein the anti-liver cancer drugs that do not contain active aldehyde groups include lenvatinib, sorafenib, regorafenib, gefitinib, lapatinib, irinotecan, fluorouracil, and oxaliplatin.
7. The use according to any one of claims 2 to 6, wherein the agent intervening in the expression of aldose reductase is an inhibitor of aldose reductase; Optionally, the aldose reductase inhibitor includes Epalrestat, Sulindac, Fidarestat, and Ranirestat.
8. The use according to any one of claims 2 to 6, wherein the agent intervening in the expression of aldose reductase is an agent knocking down the expression level of the AKR1B1 gene. 9 . The use according to claim 8 , wherein the reagent for knocking down the expression level of the AKR1B1 gene is a reagent for knocking down the expression level of the AKR1B1 gene based on the principle of lentiviral transfection.
10. A drug for treating liver cancer patients who are resistant to systemic liver cancer treatment drugs, wherein the systemic liver cancer treatment drug is an anti-liver cancer drug that does not contain an active aldehyde group, and the drug comprises a combination of epalrestat and lenvatinib.
Citation Information
Cited By
Application of AKR1B10 inhibitor in preparation of medicine for improving adoptive gamma delta T cell therapy
CN120789058A
Use of akrb10 inhibitors in the manufacture of improved adoptive gd t cell therapy drugs
CN120789058B
